WHO ICTRP trial
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy…
EUCTR2018-003857-73-GB · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2018-003857-73-GB |
|---|---|
| Public title | Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Myeloid Leukemia Patients. |
| Scientific title | A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia Patients Not Eligible for Intensive Induction Therapy |
| Primary sponsor | AstraZeneca AB |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | France;United States;Spain;Germany;Italy;United Kingdom |
| Conditions | Treatment Naïve or Relapsed/Refractory Acute Myeloid Leukemia;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Product Name: AZD2811 suspension for constitution for infusion Product Code: AZD2811 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: AZD2811 CAS Number: 786684-28-4 Current Sponsor code: AZD2811 Concentration… |
| Registration date | Mar 4, 2019 |
| Target size | 130 |
| Secondary IDs | D6130C00003;NCT03217838;HEMREF 41 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: